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Simple Summary: In classic Hodgkin lymphoma, T and NK cells constitute a significant fraction of
the reactive microenvironment established by malignant Hodgkin Reed–Sternberg cells. Despite their
abundance, T and NK cells remain largely ineffective because of two coordinated levels of immune
evasion. The first is based on the acquisition of regulatory properties or exhausted phenotypes that
cripple their antitumor activity. The second is represented by their peculiar spatial distribution,
with the most immunosuppressive subpopulations lying in close proximity of neoplastic cells. Recent
discoveries about the functional role and the spatial orientation of T and NK cells in classic Hodgkin
lymphoma are the focus of this review.
Abstract: Classic Hodgkin lymphoma (cHL) is a unique lymphoid neoplasm characterized by
extensive immune infiltrates surrounding rare malignant Hodgkin Reed–Sternberg (HRS) cells.
Different subsets of T and NK cells have long been recognized in the cHL microenvironment, yet their
distinct contribution to disease pathogenesis has remained enigmatic. Very recently, novel platforms
for high dimensional analysis of immune cells, such as single-cell RNA sequencing and mass cytometry,
have revealed unanticipated insights into the composition of T- and NK-cell compartments in cHL.
Advances in imaging techniques have better defined specific T-helper subpopulations physically
interacting with neoplastic cells. In addition, the identification of novel cytotoxic subsets with an
exhausted phenotype, typically enriched in cHL milieu, is shedding light on previously unrecognized
immune evasion mechanisms. This review examines the immunological features and the functional
properties of T and NK subsets recently identified in the cHL microenvironment, highlighting their
pathological interplay with HRS cells. We also discuss how this knowledge can be exploited to predict
response to immunotherapy and to design novel strategies to improve PD-1 blockade efficacy.
Keywords: classic Hodgkin lymphoma; microenvironment; T cells; NK cells; PD-1 blockade;
immunotherapy
1. Introduction
Classic Hodgkin lymphoma (cHL) accounts for 15% to 25% of all lymphomas, and is characterized
by a bimodal distribution with an increased incidence among young adults and subjects of 55 years and
older [1]. Traditional treatment approaches, combining chemotherapy and radiotherapy, have led to a
high cure rate between 60% and 90%, mostly dependent on disease stage. Second line chemotherapy
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followed by autologous stem cell transplantation can rescue a proportion of relapsed/refractory
(R/R) patients, but long-term toxicities still represent a major concern [1]. Since this disease was
discovered [2], the unique features of its inflammatory microenvironment have intrigued generations of
pathologists and clinicians, who devoted much energy to characterize the nature of immune cells and
the reciprocal interactions between the neoplastic and reactive components. The malignant Hodgkin
Reed–Sternberg (HRS) cells, which are distinguished into mononuclear (Hodgkin) and binucleated
(Reed–Sternberg) forms [3,4] and constitute only a minor fraction (1–2%) of the overall tumor cellularity,
are embedded within an extensive, yet functionally inefficient, immune infiltrate composed of
lymphocytes, monocyte/macrophages, neutrophils, eosinophils, and NK cells [5]. T lymphocytes are
the most abundant immune cells in the cHL milieu and encompass a variety of subpopulations with
different localizations, multiple patterns of interaction with HRS cells and macrophages, and divergent
functional properties [5]. Over the past thirty years, three distinct perspectives have alternatively
dominated our understanding of cHL T-cell microenvironment (Figure 1).
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Figure 1. Timeline of T-cell infiltrates in cHL. Represented are the key milestones driving the
understanding of T-cell infiltrates in cHL. The original view that the cHL tumor microenvironment
(TME) is dominated by Th2 and Treg cells was challenged by evidences supporting the presence of
numerous Th1 cells. More recently, the discovery of novel T-cell subsets and the analysis of their
spatial relationships are adding further complexity to the cHL TME and may be useful to design novel
microenvironment-based therapeutic strategies.
The initial evidence for the presence of a T helper (Th) 2-biased milieu in cHL was
based on early immunohistochemistry data showing the majority of infiltrating T cells were
CD45RO+CD45RA-CD45RBlow [6–9]. This pattern of expression was originally interpreted as a
Th2-skewed phenotype because CD45 isoforms were thought to discriminate Th1/Th2 polarization,
rather than T-cell differentiation status (naïve/antigen-exposed, see next section for more details) [6,7,10].
Moreover, the lack of high-throughput technologies limited the analysis to a few selected markers,
potentially insufficient to capture the heterogeneity of the cHL microenvironment. Later, large infiltrates
of regulatory T cells were identified in cHL and thought to be the major responsible for local immune
evasion [11]. In 2013, flow cytometric analyses of single cell suspensions from cHL lymph nodes,
together with tissue microarray immunohistochemistry, have challenged this view, showing the
CD4+ infiltrate was mostly Th1 polarized and retained proliferative capacity and a cytokine-secretory
phenotype as well [10]. More recently, mass cytometry [12], enabling the simultaneous detection
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of more than 40 markers in millions of individual cells, and single-cell RNA sequencing [13] have
added tremendous insights into the cellular composition of cHL tissues, providing novel information
about T and NK cells surrounding, and sometimes contacting, HRS cells. Two general paradigms are
emerging. First, there is remarkable heterogeneity within reactive T-cell compartment of cHL nodes.
Second, the spatial localization of T and NK cells, so far relatively neglected, may follow a histological
hierarchy established by HRS cells, in which the most immunosuppressive subpopulations directly
contact neoplastic cells and participate in the formation of the so-called immune-privileged niche.
Such biological advances are being translated into the clinical ground, and are helping explain why
cHL is one of the most sensitive to PD-1/PD-L1 axis inhibition among human cancers.
2. Overview of T-Cell Differentiation, Polarization and Activation Status
T cells are distinguished into two broad classes based on the expression of CD4 and CD8
co-receptors. CD4+ T-helper cells detect peptide antigens in the context of MHC class II (MHC-II)
molecules and govern the adaptive arm of the immune response by producing cytokines and
chemokines with either pro-inflammatory or regulatory roles. Instead, CD8+ cytotoxic T cells detect
antigen presented by MHC class I (MHC-I) complex and elicit lytic responses that directly kill neoplastic
or virus-infected cells [14]. Two parallel processes drive the peripheral fate of CD4+ and CD8+ T
lymphocytes: cell differentiation and subset specification (Figure 2).
T-cell differentiation states include naïve T cells, which have never encountered the antigen
before, central memory (CM) T cells, effector memory (EM) T cells, and terminally differentiated T
cells (TEMRA) [15]. Each of these clusters exhibits a distinct repertoire of surface receptors, and the
analysis of CD45, CCR7, CD62L and CD95 is utilized for their proper identification [15]. The transition
from naïve to terminally differentiated cells is characterized by a progressive change in the epigenetic
and transcriptional profile, which parallels the acquisition of effector functions. Overall, an increased
differentiation status positively correlates with the production of inflammatory and lytic molecules,
but limits self-renewal capacity and longevity [16].
Subset specification allows T cells to specialize their response based on the cytokine environment
they are exposed to. Most cytokines signal through the JAK/STAT pathway, with different members of
the STAT family promoting functionally divergent T-cell subsets, and initiating the transcription of
different T-cell master regulators [16]. STAT4 and STAT1, phosphorylated in response to IL12 or IFNγ,
respectively, transactivate T-bet and switch cell polarization into a Th1 phenotype [17]. STAT5 and
STAT6 define the Th2 subset by upregulating the transcription factor GATA3 [17]. Th17 polarization
is induced by IL6 and IL23 via STAT3/RORc axis [18], whereas T-regulatory (Treg) differentiation is
promoted by Foxp3 via STAT5 phosphorylation [19]. Although the lineage specification has been
extensively studied in CD4+ T cells, cytotoxic T lymphocytes can be categorized similarly, and subsets
producing type 1, type 2 cytokines, or even IL17 have been clearly identified and termed Tc1, Tc2 and
Tc17, respectively [15].
As discussed below, the composition of T-cell compartment in cHL differs from that of reactive
lymph nodes (RLNs), both in terms of differentiation state and subset specification [20]. Additionally,
a more nuanced view of subset-defining transcription factors [16] should be considered while dissecting
the cHL milieu, as populations co-expressing multiple transcriptional regulators have been increasingly
described [20]. Because HRS cells release a variety of soluble factors involved in T-cell chemotaxis
and polarization, they control almost every aspect of T cell biology in cHL tissue, spanning from
recruitment to lineage polarization and functional exhaustion.
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Figure 2. Differentiation and polarization of T cells. CD4+ T-cells differentiate from naïve to effectors
(EFF), effector memory (EM) and central memory (CM) cells. CD8+ T-cells progress from naïve to
CM, EM and terminal effector memory re-expressing CD45RA (TEMRA). CD4 and CD8 differentiation
states can be distinguished by the expression of the indicated markers. In parallel, antigen-exposed
CD4+ T-cells acquire one or more master regulators that specify the subset of functional polarization.
Though less studied, a similar process seems to be operational also in CD8+ T-cells.
3. The Hodgkin Reed-Sternberg Secretome: Combinatorial Signals for T-Cell Recruitment
HRS cells release a vast array of cytokines and chemokines actively contributing to build up the
unique cHL microenvironment [21].
CCL5 is a chemokine secreted by cHL cells upon CD40 stimulation, which is provided by
CD4+CD40L+ T-lymphocytes rosetting HRS cells [22]. The CCL5 cognate receptor, CCR5, is usually
expressed on circulating T cells, which migrate to neoplastic tissues following CCL5 gradients [23].
In addition, CCR5 is expressed on HRS cells and stimulates their proliferation upon interaction with
CCL3, CCL4 and CCL5 [22]. Therefore, the CCL5/CCR5 axis provides autocrine and paracrine signals
favoring tumor growth ei her th ough direct ffects on cancer cells or enhancement of microenvironment
formation. Indeed, CCR5 antagonism by maraviroc disrupts the interactions between tumor and
reactive cells, impairing tumor xenograft growth without significant toxicity [24].
CCL11, also known as eotaxin, is secreted by cHL-associated fibroblasts following stimulation
with HRS-derived TNFα [25]. Upon binding to CCR3, which is considered a Th2 marker [26],
CCL11 promotes chemotactic responses of Th2 cells, suggesting that the stromal component of cHL
lymph nodes can be educated by neoplastic cells to sustain the recruitment of immunosuppressive
T-cell populations [25].
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CCL17 (TARC) is another chemokine involved in Th2-cell recruitment. Van den Berg and colleagues
showed the L428 cell line and several primary cHL tissues expressed CCL17, while anaplastic T-cell
lymphomas and diffuse large B-cell lymphoma were mostly negative [27]. CCL17 binds to its receptor
CCR4, usually detected on Th2 lymphocytes and responsible for their chemotactic migration [27].
CCL22 shares the same receptor as CCL17 and is also secreted by HRS cells. The concentration of
both chemokines increases in sera from cHL patients with active disease and sharply decreases after
treatment [28]. Mogamulizumab, an anti-CCR4 monoclonal antibody, exhibits clinical activity in
CCR4+ systemic and cutaneous T-cell lymphomas, and may be of some benefit in contrasting the cHL
microenvironment [29].
CCL20 (MIP3α) is a CC chemokine detected in a subset of cHL cell lines (L428, KM-H2,
and L591) and primary tumors [30]. CCL20 gene transcription is induced by the IL21/STAT3 axis,
which is constitutively active in the cHL cell lines expressing both IL21 and IL21 receptor [30].
CCL20 recruits CCR6+ T lymphocytes, including Th17, Tregs, and a subset of Th1 [31].
CCR6+CD4+CD25+Foxp3+CD127low regulatory cells are particularly enriched upon CCL20 stimulation
and likely contribute to local immune evasion [30]. CCL20 expression in HRS cells can be also
upregulated by the EBV-nuclear antigen 1 EBNA1 [32], indicating that EBV infection plays an
active role in establishing the reactive microenvironment. In addition, EBV latent Membrane
Protein 2A (LMP2A) induces IL10 gene transcription by HRS cells through PI3K activation and
STAT3 phosphorylation [33]. Because IL10 polarizes tumor-associated macrophages (TAMs) into the
immunosuppressive, M2 phenotype [34], multiple EBV-related proteins end up blunting the anti-tumor
potential of inflammatory cells. In accordance, elevated pre-treatment serum IL10 is associated
with decreased progression-free survival (PFS) in cHL patients treated with either chemotherapy or
radiation [35,36].
As reported by Machado and colleagues, several other T-cell homing molecules are detectable
within the vasculature of cHL lesions. CCL21, CXCL10 and CXCL12 are expressed by HRS cells and/or
vascular endothelium, while the cognate receptors CCR7, CXCR3 and CXCR4 are detected on a large
proportion of T cells infiltrating the neoplastic tissue [37]. Moreover, HRS cell-derived lymphotoxin-α
induces upregulation of adhesion molecules, such as ICAM-1, VCAM-1, and E-selectin, on vascular
endothelium, further promoting T-cell recruitment into cHL lymph nodes [38]. Additional soluble
factors attracting other components of the cHL microenvironment have been recently reviewed by
Aldinucci et al [39].
4. The Spectrum of T-Helper Subsets in the cHL Microenvironment
T helper lymphocytes are the predominant T-cell population in cHL lymph nodes.
A mass-cytometry-based, comparative analysis between RLNs and cHL cases revealed that Th1
effector memory (Th1 EM) and Th1 Treg were the main CD4+ subsets expanded in cHL tissues [20].
Th1 EM cells were defined as CCR7-CD45RO+EOMESlow effector lymphocytes co-expressing the
Th1 transcription factor T-bet and the inhibitory co-receptor programmed death-1 (PD-1). As such,
they likely represented an exhausted phenotype with low anti-tumor abilities, but potentially amenable
to PD-1 blockade [20]. Th1 Tregs were CD25+Foxp3+ cells expressing T-bet but mostly PD-1-negative.
This population had features associated with a memory phenotype (CCR7lowKi67low) and probably
acts as a functionally active, immunosuppressive subset contributing to local immune evasion [20,40].
Therefore, a large proportion of the T-bet+ infiltrate turns out ineffective in cHL, owing to the
peculiar coexistence of subpopulations functionally restrained by either PD-1 expression or regulatory
cellular programs.
From a genomic standpoint, the Treg infiltrates of cHL and reactive tonsils show remarkable
differences [41]. cHL Tregs, defined by Wein et al. as CD4+CD25highCD127−, had higher levels of
CD38 and autotaxin transcripts, involved in the modulation of purinergic signaling [41]. Moreover,
the transcription of BTLA and CD200R, two genes encoding surface receptors with immunosuppressive
functions, was upregulated by cHL Tregs. This may represent an additional immune-evasion
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mechanism as a subset of cHL cell lines expresses CD200 [41]. In vitro experiments also showed that
Treg polarization was acquired by naïve CD4+ T-cells when co-cultured with cHL cell lines [41]. Unlike
Th1 and Treg cells, the Th2 subsets are usually less represented in cHL tissues compared to RLNs.
Th2 central memory (Th2 CM) and Th2 Treg cells are less abundant in cHL and their contribution in
suppressing anti-lymphoma immunity is probably weaker than thought in the past [20,42]. In addition,
they usually stain negative for PD-1, thus playing a minor role in the immune-checkpoint priming
typically carried out by the PD-1+ Th1 subsets [20].
The extent of Th17 infiltrate in cHL is somehow more controversial, due to the different technical
approaches across the studies (genomics, immunohistochemistry, mass cytometry), the different
markers utilized for its identification, and the heterogeneity of cHL biology [20,31,43,44]. Overall,
CD161+CCR4+ Th17 cells are less abundant in cHL than RLN [20]. However, about 40% of cHL
cases display an IL17-enriched microenvironment, with histological evidence of IL17+ and even
double positive Foxp3+IL17+ T cells, mostly located outside the close proximity of HRS cells [31].
Whether these subsets are counteracting the exhausted immune populations or rather represent another
facet of cHL immune privilege is matter of ongoing investigations. Recently, a positive correlation
between Treg/Th17 ratio and survival rate was shown in cHL patients [45], suggesting that large Th17
infiltrates may increase disease aggressiveness. Factors released by HRS, such as IL6, IL21, IL23,
and soluble CD30 (sCD30) [46] can favor Th17 polarization [31,43,47,48], which, in turn, promotes
the recruitment of myeloid cells and amplifies the inflammatory infiltrate [49]. Two independent,
genomic-based analyses of the cHL microenvironment demonstrated the Th17-skewed immune
profile was more common among EBV− cases as compared to the positive ones [43,44]. Accordingly,
the transcriptomic signature of EBV− cHL showed the engagement of the IL23/IL17 axis, leading to
STAT3 phosphorylation and nuclear translocation. By contrast, most EBV+ tumors were Th1-biased,
with coordinate expression of T-bet, IFNγ and IDO genes [43,50]. In this context, the expansion of
regulatory type 1 (Tr1) lymphocytes may be of substantial importance to allow HRS cells evading
immune attack. Tr1 lymphocytes have been detected in both tumor tissue and peripheral blood of EBV+
cHL patients, and configure a regulatory subset lacking Foxp3, but usually expressing integrin subunit
alpha 2 (ITGA2) and lymphocyte-activation gene 3 (LAG3) [51,52]. Tr1 cells produce high amount of
the immunosuppressive cytokine IL10, which indeed is increased in the microenvironment as well as in
serum samples of EBV+ cHL [52]. Therefore, Tr1 cells act as an additional source of IL10, which is also
upmodulated by the latent EBV infection established in EBV+ HRS cells [33]. Very recently, Tr1 cells
in the cHL milieu were further characterized and a distinct Foxp3−, Tr1-type T-cell subpopulation,
staining positive for LAG3, CD25 and glucocorticoid-induced TNFR-related protein (GITR), has been
identified irrespective of EBV positivity [44]. This LAG3+ cluster was significantly more evident in
cHL cases compared with RLNs and its expansion was enhanced in vitro by culturing normal T cells
with HRS cell supernatant. In particular, IL6 released by tumor cells played a major role in promoting
LAG3+ cell polarization. Conversely, direct interaction with MHC-II, known to be a LAG3 ligand,
led to LAG3 downmodulation, a mechanism accounting for the induction and persistence of LAG3+
cells in MHC-II-negative cHL cases [44]. Consistent with their immunosuppressive profile, LAG3+
cells expressed very high levels of IL10 and TGF-β, and impaired the proliferation of co-cultured CD4+
T-cells in vitro [44]. The LAG3+ subset in cHL also exhibited a peculiar repertoire of immunoreceptors,
characterized by the expression of cytotoxic T-lymphocyte antigen 4 (CTLA4), which is considered
a universal marker of regulatory T cells [53], and the lack of PD-1 [44]. As a consequence, LAG3+
cells represent an immunosuppressive population particularly enriched in MHC-II-negative cHL,
and insensitive to antibodies targeting PD-1/PD-L1 axis.
CTLA4 is expressed more broadly than LAG3 on T cells populating the cHL microenvironment [54].
Patel and colleagues have recently found that CTLA4+ T cells, usually staining negative for Foxp3,
outnumbered PD-1+ and LAG3+ cells in cHL. Moreover, HRS cells and a fraction of TAMs were
positive for the CTLA4 ligand CD86, whose engagement led to T-cell receptor (TCR) complex signaling
inhibition [53]. Importantly, CTLA4+ T-cell infiltrate was further enriched in relapsed/refractory
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cHL patients, suggesting it might protect HRS cells from currently employed therapeutics, including
anti-PD-1 antibodies [54].
5. Contribution and Localization of CD8+ T Cells in the cHL Microenvironment
Cytotoxic T cells are less abundant than Th cells in the cHL microenvironment, and their role in the
pathogenesis of the disease has been recently downsized due to the low expression of β2-microglobulin
and MHC-I on HRS cells in 79% of patients [55]. Because CD8+ T cells detect antigens in the context of
MHC-I, HRS cells are invisible to the cytotoxic arm of T-cell immunity in a substantial proportion of
cases. Nevertheless, in cHL cytotoxic T cells carry a peculiar differentiation profile, a biased polarization
toward Tc1 phenotype, dysfunctional traits, and distinct intratumoral localization. Comparing to RLNs
and tonsils, cHL tissues are enriched for EM and TEMRA CD8+ cells, whereas naïve and CM CD8+
cells are relatively fewer [20]. Together with a more differentiated profile, cHL cytotoxic T cells are also
more Tc1-polarized and stain positive for granzyme B (GrB). By contrast, Tc2 cells are less frequent
and overall less differentiated, with a prevalence of CM and a lack of EM Tc2 cells [20]. The increased
terminal differentiation of cytotoxic T cells seems particularly evident in EBV+ cHL tumors, where
MHC-I-dependent antigen presentation is more often intact [20,56]. EBV- and tumor-derived antigens
persistently engage T-cell receptor and drive the development of dysfunctional states typically associated
with a terminally-differentiated phenotype [57]. CD8+ dysfunction progresses along a gradient of cell
states with different proliferation capacity and functional properties. While pre-dysfunctional cells are
highly proliferating and express checkpoint inhibitors at intermediate levels, overtly dysfunctional
CD8+ cells lose their proliferative thrust and increase the expression of checkpoints molecules such as
CTLA4, LAG3 and PD-1 [58]. Traits of CD8 dysfunction are frequently encountered in cHL tissues.
Multiplexed immunofluorescence imaging data have shown the density of CD8+CTLA4+ cells is
higher in cHL cases compared with RLNs [54]. Moreover, most EM Tc1 cells express PD-1 [20], further
highlighting the right-shift along the CD8+-cell dysfunctional axis [58]. An additional cytotoxic subset
coexpressing CXCR5 and inducible T-cell costimulator (ICOS) has been recently identified in 7% of cHLs
and still recapitulates the hallmarks of dysfunctional cells [59]. CD8CXCR5+ICOS+ cells have deficient
cytotoxicity, secrete low levels of IFNγ, and support B-cell proliferation as well as antibody production
in vitro [59]. These cells are frequently located in the close proximity of reactive B lymphocytes
and produce high amounts of CXCL13, a B-cell chemoattractant responsible for the formation of
tertiary lymphoid structures in several human cancers [60]. Indeed, the presence of a CD8CXCR5+ICOS+
population defines a cHL subset characterized by nodular architecture with hyperplastic germinal
centers, only partly disrupted by the surrounding neoplastic infiltrate [59]. In addition to persistent
antigenic stimulation, other soluble and membrane-bound molecules contribute to disempower CD8+
immunity in cHL. Galectin-1 is a member of a conserved family of carbohydrate-binding proteins
frequently overexpressed by HRS cells. It induces apoptosis selectively in Th1 and cytotoxic T cells,
thus favoring the secretion of Th2 cytokines, such as IL4, IL10 and IL13, and the expansion of regulatory
T-cell subsets [61]. The abundance of galectin-1 together with the low MHC-I expression on HRS cells
probably restrain CD8+ T lymphocytes to keep direct contact with neoplastic cells.
6. Natural Killer Cells in cHL: Keeping Cytotoxicity in Check
NK cells are innate lymphoid cells exerting cytotoxic functions against malignant or virally infected
cells. Their activity is regulated by the integration of signals derived from activatory and inhibitory
receptors. Several killer-cell immunoglobulin-like receptors (KIRs), such as KIR2DL1, KIR2DL2/3,
and KIR3DL1 transmit negative signals upon binding to MHC-I molecules, whereas neural cytotoxicity
receptors (NCRs) and NKG2D respond to stress-induced stimuli and trigger NK cell activation [62].
Because the majority of cHL cases harbor inactivating mutations ofβ-2-microglobulin that lead to the loss
of MHC-I expression [63], the functional profile of NK cells residing tumor microenvironment should
be hypothetically skewed toward a persistent activation. However, independent studies have shown
this is not the case. Soluble factors released by either HRS cells or infiltrating immune subpopulations
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can blunt NK cell recruitment and activation, leading to quantitative and qualitative NK deficiency [64].
The immunosuppressive cytokines IL10 and TGF-β, frequently abundant in the cHL milieu [11],
reduce lymphocyte production of IFNγ, which would favor NK cell attraction [65]. In addition, HRS
cells secrete soluble CD25 that binds IL2 and prevents its interaction with IL2R-expressing NK cells,
limiting the availability of this pro-survival cytokine [66]. NK cell activation is further hindered by
HRS overexpression of Fas ligand (FasL), which exerts a pro-apoptotic effect on Fas-expressing NK
cells [67]. Even when NK populations resist the unfavorable cHL microenvironment, they are often
excluded from the vicinity of HRS cells. A physical barrier consisting of immunosuppressive T and
myeloid populations shields neoplastic cells from NK attack, a complementary and highly effective
immune evasion strategy [68].
Beside these general, HRS-dependent, mechanisms of NK cell exclusion, recent studies have
highlighted subtler differences in circulating NK subpopulations between cHL and healthy donors.
Overall, NK cells can be distinguished into two main subsets identified as CD56brightCD16− and
CD56dimCD16+. While the former represents an immature NK phenotype and accounts for less than
10% of all NK cells in the circulation of healthy subjects, the latter is characterized by highly cytotoxic
activity through lytic granule release and antibody-dependent cell cytotoxicity [69]. In cHL patients,
the proportion of circulating CD56brightCD16−NK subpopulation is significantly expanded as compared
to healthy donors, and partially loses the expression of the chemokine receptor CCR7 [70]. This makes
NK cells less prone to egress from the blood to the secondary lymphoid organs, other than less efficient
in antibody-triggered cytotoxicity due to the lack of CD16 (FcγRIII). Monocyte-macrophages play a
fundamental role in restraining NK cell activation, and monocyte depletion enhances the expression of
the activation marker CD137 in cHL NK cells [70]. More conflicting results concern the expression of
PD-1 in circulating NK cells. While Vari et al reported substantial PD-1 expression in CD56brightCD16−
NK cells [70], Cader and colleagues have demonstrated that PD-1 is largely absent in circulating NK
cells [20], casting doubts about the role of PD-1/PD-L1 axis in blocking NK activity in cHL.
Within the CD56dim subpopulation, a novel subset staining negative for DNAX accessory
molecule-1 (DNAM-1) has been recently identified [71]. CD56dimDNAM-1− NK cells were enriched
in the blood of cHL patients and displayed features of terminally differentiated NK cells such
as propensity to undergo apoptosis in inflammatory microenvironments, resistance to cytokine
withdrawal, and short telomeres. Compared with CD56dimDNAM-1+ NK cells, the CD56dimDNAM-1−
subset had lower proliferative potential, decreased ability to produce IFNγ in response to cytokine
stimulation, and limited killing capacities. Additionally, CD56dimDNAM-1− cells impaired the
cytolytic activity of the CD56dimDNAM-1+ counterpart through undefined soluble factors, acting like
an immunomodulatory subpopulation that further increases systemic immune evasion [71].
7. Immunosuppressive Interactions Taking Place in the Neoplastic Niche
Despite the highly polymorphic and dynamic nature of cHL reactive microenvironment, the spatial
localization of distinct immune subsets is all but random. Multiplexed immunofluorescence and
imaging mass cytometry, enabling the simultaneous detection of multiple epitopes within a tissue
section [72,73], have been exploited to unravel the cell-interaction network underlying cHL architecture.
The emerging framework is that different reactive subpopulations occupy specific micro-areas and
preferentially contact a few selected cell types (Figure 3). The HRS proximal region, also termed
neoplastic niche and defined in two consecutive studies as the area within 75 µm of a given HRS
cell [54,68], is usually enriched in PD-1+CD4+ T cells, which physically interact with both PD-L1+
cancer cells and PD-L1+ TAMs [68]. Additionally, the CD4+ population as a whole is more likely to
be in close contact with HRS cells compared to the CD8+ T-cells, which show no enrichment around
HRS cells [68]. The CTLA4+ T-regulatory subset is more represented in the HRS proximal region
as well, and interacts with PD-L1+CD86+ TAMs [54]. Therefore, the immunosuppressive TAMs
expressing PD-L1 and possibly CD86 are more frequently encountered in the close vicinity of HRS
cells. This unique topology increases the local source of PD-L1 and likely augments the extent of
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PD-1 signaling. The localization of the CD4+Foxp3+ and CD4+LAG3+ T-cells remains instead more
controversial [44,54], but it may be dictated by the expression of MHC-II on tumor cells. MHC-II−
cHL cases have a high density of LAG3+ T-cells in close proximity of HRS cells [44]. In this context,
LAG3+ cells can also interact with other T-cell subsets and inhibit their proliferation and killing
abilities. Conversely, MHC-II+ cases have a few LAG3+ T-cells, but display a greater number of Foxp3+
T-lymphocytes lying in the neoplastic niche close to HRS cells [44]. CD8+ T-cells, Th17 subsets, NK cells
and PD-L1−CD86low TAMs, potentially endowed with residual anticancer cytolytic activity, populate
spatial domains that are further away from tumor cells [31,44,68]. Studies pointing out this unique
cHL topology took into account primarily diagnostic samples, with scanty information about the
spatial arrangement of relapsed tumors. Recently, Reinke S and colleagues have shown that cHL cases
progressing after PD-1 blockade have a lower number of PD-L1+ macrophages with a slight increase of
PD-1+ T-cells [74]. A previous study comparing diagnostic versus relapsed cHL demonstrated that also
CTLA4+ T-cells are increased in relapsed cases [54]. This suggests that HRS cells surviving anti-PD1
treatment may be less dependent on the original microenvironment, or acquire different abilities to
modulate such microenvironment.
Overall, the variety of regulatory/exhausted T-cell populations and the highly organized topology
of cHL tissues concur to establish a neoplastic niche with robust mechanisms of immune evasion.
The interactions at the interface between HRS and rosetting CD4+ T-cells can be functionally categorized
into two types. The first one is critical to stabilize CD4+ T-lymphocytes in the close proximity of
HRS cells. It is represented by CD58/CD2 and, to a lesser extent, MHC-II/TCR interactions, which
form an immunological synapse between neoplastic and T cells, and lead to the local accumulation
of rosetting T-cells [75]. The second type of interactions serves to dampen T-cell antitumor activity
and includes PD1/PD-L1, CTLA4/CD86 and LAG3/MHC-II interactions [76–78]. PD-1 engagement
leads to phosphorylation of its immunoreceptor tyrosine-based switch motif and recruitment of
SHP2, a phosphatase that inhibits ZAP70 and the co-stimulatory molecule CD28 in T cells [76].
The outcome is the attenuation of signaling branches derived from TCR and CD28 stimulation,
including PI3K/AKT and RAS-MEK-ERK pathways [76]. Importantly, reverse signaling via PD-L1
can prevent apoptosis, stimulate mitochondrial oxidative phosphorylation, and favor proliferation
of HRS cells in vitro [79], indicating that PD-1/PD-L1 axis can have direct pro-tumoral effects in
addition to suppressing anti-tumor immunity. CTLA4 inhibits TCR via competition with CD28 for
the ligands CD80 and CD86, for which CTLA4 has higher affinity and avidity. CTLA4 mitigates,
therefore, the positive signals specifically originating from the co-stimulatory molecule CD28 [77].
Lastly, LAG3 binds MHC-II on HRS and antigen-presenting cells, with stronger affinity than CD4.
As a consequence, LAG3 prevents the TCR complex/MHC-II interactions, directly dampening TCR
signaling and impairing T-cell proliferation and cytokine production [78].
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Figure 3. Preferential localizations of T-cell subpopulations in cHL. CD4+ T-cells localize in close
proximity of HRS cells and form the typical rosettes. In particular, PD-1+ T-cells and CTLA4+ T-cells
have been identified in contact with HRS cells and promote local immune evasion; LAG3+ T-cells
have been described in the vicinity of HRS cells by some, but not all, authors. They are supported
by HRS-derived IL6, and secrete IL10 and TGF-β that promote HRS survival and further suppress
local immunity. CD58/CD2 interaction is critical for the establishment of the immunological synapse
between HRS and CD4+ T-cells, and sustains the IL2-mediated autocrine signaling that leads to reactive
T-cell expansion. Functional polarization of these checkpoint-defined T-cell subpopulations has yet
to be determined, albeit Th1 subset should be the most abundant. Most of rosetting CD4+ T-cells
participate in inhibitory interactions with HRS cells and PD-L1+ macrophages, which are also enriched
nearby HRS cells. Outside the neoplastic niche, here represented by the yellow area surrounding the
HRS cell, there are Th17 cells, PD-L1- macrophages, CD8+ lymphocytes (mostly EM Tc1, with some
variations depending on EBV status, see text) and a few NK cells. These potentially hostile populations
are usually kept far away from neoplastic cells.
8. How HRS, T and NK Cells Predict Response to PD-1 Blockade
Until 2015, therapy of cHL was mostly directed to the neoplastic component. Although combination
chemotherapy, radiation, and anti-CD30 immunoconjugates yi ld d successful results, a small but
signific nt fraction of cHL patients still died of their disease [1]. In 2015–2016, th res lts of two pha e
1 trials testin the a ti-PD-1 antibodies nivolumab and pembrolizumab showed highly encouraging
response rates with acceptabl safety profile in heavily pre-treated populations [80,81], op nin the
way to novel, microenvironment-dir cted strategies in th management of this isease. The results of
th phase 2 tri ls Checkmate 205 (niv lumab) and KEYNOTE-087 (p brolizumab) involving R/R
cHL patients showed an over ll response rate (ORR) of 71% and 72%, with complete remission (CR)
achie ed in 21% and 28% of patients, respectively. The median durati n of response was 18 months in
the Checkmate 205 trial and 6.5 months in the KEYNOTE-087 [82,83].
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With the aim of identifying biomarkers of response to PD-1 blockade, fluoresce in situ hybridization
(FISH) assay was performed to characterize copy number alterations of PD-L1 in biopsy specimens
from cHL patients. Ninety-seven per cent of cHL cases had abnormalities in the PD-L1 and PD-L2 loci,
including polysomy (5% of cases), copy gain (56%), and amplification (36%) (55,84). The same amplicon
at 9p24.1 almost always includes the JAK2 gene, leading to increased JAK/STAT signaling in HRS cells
and further induction of PD-L1 expression [84]. Constitutively active JAK/STAT pathway also promotes
IL6, IL13 and CCL17 synthesis, thus contributing to recruit and polarize reactive cells [85]. Patients
with higher-level 9p24.1 copy gain and increased expression of PD-L1 specifically on HRS cells had
superior PFS after nivolumab treatment. Moreover, while MHC-I expression did not predict clinical
outcome, MHC-II positivity on HRS cells was associated with better chances to achieve a CR [84].
This suggests that the CD4+ infiltrate rather than the CD8+ one might be the major determinant of
the therapeutic activity of PD-1 inhibitors. Indeed, studies on murine solid tumor models revealed
that PD-1 blockade exerted anticancer effects against MHC-I−MHC-II+ but not MHC-I−MHC-II−
tumors. In addition, the anticancer activity of anti-PD-1 antibodies was abolished in mice depleted of
CD4+ T-cells, but not CD8+ T-cells [86]. Independent studies have also shown that Th lymphocytes
may mount a cytolytic response in appropriate contexts [86,87]. Mice bearing MHC-II+ tumors had
larger amounts of intratumoral CD4+ T-cells that stained positive for GrB, and this subset further
increased following PD-1 blockade [86]. Similarly, a candidate circulating CD4+ “cytotoxic” T-cell
subset (GrB+PD-1+ with EM phenotype) has been identified in cHL patients, particularly in the R/R
setting. A CD4+ GrB+, but CD3−, innate subpopulation was also detected both in the circulation and
in the tumor microenvironment of relapsed cHL cases, and was associated with a favorable response
to nivolumab [87].
Additional factors potentially predicting good outcome following checkpoint inhibitors are T-cell
diversity and NK cell abundance. In comparison with healthy subjects, cHL patients, especially those
with R/R disease, have a significantly reduced TCR repertoire. In the Checkmate 205 trial, treatment
with nivolumab was more effective in patients having a diverse peripheral TCR repertoire and an
expansion of singleton T-cell clones during treatment. Patients with a highly significant increase in
CD4+, but not CD8+, TCR diversity after 6 weeks of PD-1 inhibition were more likely to achieve a
CR. Likewise, patients with more abundant circulating mature NK cells (CD56dimCD16+) had better
clinical outcome after nivolumab [87].
9. Translational Insights to Improve Immunotherapy Results
In general, cHL holds the highest reported responses to PD-1 inhibition in any tumor type [82,83],
likely because of its genetically driven PD-L1 upregulation, the high mutational burden, the high
frequency of MHC-II expression on HRS cells, the CD4+-enriched microenvironment and the abundance
of PD-L1+ TAMs. The combination of these features renders cHL a lymphoid neoplasm uniquely primed
for PD-1 blockade [88]. However, the robustness of complementary immune-evasion mechanisms
typical of cHL (Figure 3) may be responsible for the primary and acquired resistance to anti-PD-1
treatment, as well as for the low rate of CRs. Upregulation of alternative immune checkpoints
has already been associated with adaptive resistance to anti-PD-1 agents in solid tumors [89].
Therefore, novel strategies aiming at potentiating the effect of PD-1 blockade or switching to different
microenvironment-targeting agents are worth being tested in cHL (Figure 4).
One of the most promising approaches consists in combining PD-1 blockade with low-dose
hypomethylating agents (Figure 4, upper panel). Pre-clinical in vivo studies have reported that
reinvigoration of exhausted CD8+ T-cells (TEX) is only temporary after PD-1/PD-L1 axis inhibition
due to the limited epigenetic flexibility of TEX [90,91]. Essentially, TEX fail to remodel their epigenetic
landscape upon treatment with anti-PD-1 antibodies, preventing the acquisition of a memory phenotype.
Thus, the persistence of HRS-derived antigenic stimulation can cause TEX to enter a “re-exhausted”
phenotype, with low anti-tumor activity. Based on the hypothesis that epigenetic modifiers may
improve the long-term durability of T-cell reinvigoration, a phase II trial testing the combination of
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decitabine (a hypomethylating drug currently approved for myelodysplastic syndrome and acute
myeloid leukemia) and camrelizumab (a fully humanized anti-PD-1 antibody) has been conducted [92].
In R/R patients who were anti-PD-1 naïve, CR rate with the combination therapy doubled as compared
to camrelizumab alone (71% vs. 32%), and the response duration rate at 6 months was 100% for
the combination versus 76% for camrelizumab alone [92]. Though encouraging, these results need
to be validated in larger clinical trials. Moreover, because the efficacy of PD-1 blockade in cHL
mainly depends on CD4/MHC-II rather than CD8/MHC-I system [84], it seems reasonable that
additional biological mechanisms may underlie the synergism between hypomethylating drugs and
PD-1 blockade.Cancers 2020, 12, x 12 of 20 
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Figure 4. Three microenvironment-based strategies to improve PD-1 blockade or as alternatives thereof.
The first and second boxes, outlined in yellow, illustrate two different strategies to improve the efficacy
of PD-1 blockade. These include the combination with hypomethylating agents, which can reinvigorate
exhausted T-cells, and the simultaneous perturbation of concurrent HRS/immu e cell interactions.
The third box, outlined in re , depicts alter atives to PD-1 blockade potentially us ful for patients
witho t biol gic l predictors of response to checkpoint inhibit rs or after heir failure.
A second way to enhance immunotherapy might be the simultaneous perturbation of multiple
immune interactions (Figure 4, middle panel). As discussed earlier, CD4+ T-cells expressing the
inhibitory co-receptor CTLA4 are particularly abundant in cHL, frequently contact HRS cells, and are
further enriched after PD-1 blockade [54]. A phase 1b trial has been conducted to address if the
combination of nivolumab plus ipilimumab, an anti-CTLA4 antibody, could be safe and possibly
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improve clinical responses compared to nivolumab alone. Disappointingly, the ORR and CR rate for the
combination (74% and 23%, respectively) were similar to those previously reported for nivolumab alone.
In addition, the toxicity of the combination was higher than expected from single-agent nivolumab [93].
Despite this, future clinical investigations may define patient subsets particularly benefiting from this
combination. At least in solid tumors, anti-CTLA4 treatment requires intact MHC-I system to effectively
exert antitumor activity [94]. Therefore, it is tempting to speculate that ipilimumab ± nivolumab
might confer a clinical advantage in the minor fraction of cHL patients with low/absent MHC-II but
conserved MHC-I expression. Beside PD-1 and CTLA4, LAG3 is an additional targetable checkpoint.
Several anti-LAG3 antibodies have being developed and some of them are in early-phase clinical trials
for R/R lymphomas (NCT03489369, NCT03005782, NCT02061761). A preclinical study by Burova and
colleagues showed that REGN3767, a fully human antibody targeting LAG3, increased the efficacy
of PD-1 blockade in a humanized mouse model and enhanced the production of pro-inflammatory
cytokines by tumor-specific T lymphocytes [95]. Similarly, combining PD-1 blockade and the anti-LAG-3
antibody LBL-007 resulted in more effective control of tumor growth than the single agents alone [96].
Preliminary data from a phase 1/2 study in melanoma patients showed the combination of nivolumab
with BMS-986016 (IgG4 antibody targeting LAG3) had similar safety profile to nivolumab monotherapy,
with encouraging efficacy [97]. Modulating HRS-NK interactions to unleash NK cell cytolysis is being
explored and combined with PD-1 blockade. AFM13 is a CD30/CD16A bispecific antibody acting
as an innate immune engager. It creates a bridge between CD30, expressed on HRS cells, and the
activating receptor CD16A, expressed on NK cells and to a lesser extent on macrophages and γ/δ T
cells. A phase 1 dose-escalation study showed AFM13 monotherapy was well-tolerated and active in
brentuximab vedotin-refractory patients. Additionally, AFM13 resulted in significant NK-cell activation
and reduction of sCD30 in peripheral blood [98]. A subsequent phase 1b trial testing the combination of
AFM13 with pembrolizumab demonstrated that the combination had similar safety profile compared
to each agent alone, with a promising ORR of 83% [99]. Therefore, CD16A engagement might restore
anticancer cytotoxic properties in functionally-deficient innate immune cells, possibly synergizing
with PD-1 blockade. It remains undefined, however, the exact mechanism whereby distant cells such
as the NK population can be properly re-oriented to the HRS neoplastic niche.
A third strategy might consist in either eliminating immunosuppressive T-cell populations or
preventing their recruitment to the cHL microenvironment (Figure 4, lower panel). This approach
might represent an attractive alternative for patients lacking predictors of good response to checkpoint
inhibition, or after the failure thereof. In this context, CD25 is a convenient target because of its broad
expression on CD4+ Treg lymphocytes rosetting HRS cells [20]. 90Y-daclizumab is a radiolabeled
anti-CD25 antibody directed towards Treg cells in the cHL milieu. Its anticancer activity is due to
strong β emissions that kill both the tumor-supporting lymphocytes and, via crossfire effect, the HRS
cells nearby. Forty-six patients with R/R cHL were administered with up to seven intravenous
infusions of 90Y-daclizumab. Of those, 23 patients underwent clinical improvement, with 14 CR and 9
partial responses (PR) [100]. ADCT-301 (camidanlumab tesirine) is another CD25-targeting antibody,
conjugated to a pyrrolobenzodiazepine dimer toxin. Interim data of a phase 1 clinical study involving
heavily-pretreated cHL patients treated with ADCT-301 showed an ORR of 63%, with a CR rate of
27% [101]. However, final outcomes have not been released yet. Eliminating rosetting T-cells by
targeting the HRS/T immunological synapse might be an additional manner to deprive the neoplastic
niche of immunosuppressive populations. Because the CD2/CD58 interaction stabilizes the HRS/T
synapses [75], monoclonal anti-CD2 antibodies, already in clinical trials for T-cell lymphomas and
autoimmune conditions [102], may counter rosette formation and prove of some benefit in cHL. Lastly,
recruitment of tumor-nurturing immune subsets can be blocked by acting on chemokine/chemokine
receptor pairs. In this regard, the CCR5-antagonist maraviroc, already licensed by the US Food
and Drug administration for HIV treatment, may be repurposed for cHL based on pre-clinical data
showing inhibition of monocyte recruitment and shrinkage of tumor masses in vivo [24]. As previously
mentioned, the anti-CCR4 antibody mogamulizumab, which is being tested in T-cell lymphomas,
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might similarly counteract microenvironment formation and prove of therapeutic relevance in selected
cHL patients [29].
In addition to these microenvironment-based strategies, HRS-directed therapies may potentiate
PD-1 blockade as well. In particular, regimens based on the combination of nivolumab with the
anti-CD30 immunoconjugate brentuximab vedotin have recently been tested and may represent an
effective chemo-free option for R/R patients or for those unsuitable for chemotherapy [103]. Interestingly,
CD30 can be released by HRS cells either through the shedding of its ectodomain (sCD30) or loaded on
extracellular vesicles (EV). sCD30 alters Th1/Th17 balance [31] while CD30-loaded EV can be absorbed
on reactive immune cells that become potential targets of anti-CD30-based immunotherapy [104].
Therefore, brentuximab vedotin and anti-CD30 CAR-T cells [105] may have yet poorly defined
immunomodulatory roles in addition to their direct effects against tumor cells.
10. Concluding Remarks
The data reviewed herein point to a meticulous arrangement of the environment surrounding
HRS cells, potentially actionable with an increasing number of targeted agents. Spatially-resolved
immunologic studies have enabled to identify niches of immunoprotection where HRS cells are
sheltered by a double layer of reactive cells: a) the CD4+ infiltrate, composed of exhausted PD-1+ T
cells, active Tregs, and additional CTLA4+ and LAG3+ subsets, whose abundance may depend on
disease status (treatment-naïve vs. R/R) and MHC-II expression; b) the PD-L1+ macrophages, likely
polarized by the cytokine milieu. Although peculiar genetic bases and a primed microenvironment
put cHL at the top of the PD-1-blockade-sensitive human cancers, important questions remain to be
addressed. Indeed, the effector mechanisms elicited by the CD4+ T cells following anti-PD-1 treatment,
and whether HRS cells are sensitive to CD8+ T-cell reinvigoration, remain to be determined. Moreover,
the immune environment of cHL may change in relation to disease status and prior therapies. Now that
PD-1 blockade is increasingly used in clinical practice, it would be valuable to understand the impact
of temporally-distinct microenvironments on checkpoint inhibitor activity. Future research will shed
further light on the immune architecture around HRS cells, with the hope to maximize the results
of immune-oncology manipulation in cHL. R/R cases, treatment-naïve patients with unfavorable
prognostic factors, and elderly patients unsuitable for chemotherapy may particularly benefit from
PD-1 blockade-based strategies in the near future.
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